<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00752193</url>
  </required_header>
  <id_info>
    <org_study_id>2008/438</org_study_id>
    <nct_id>NCT00752193</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of a Vaginally Administered Probiotic Lactobacilli Delivery System.</brief_title>
  <official_title>Safety and Efficacy of a Vaginally Administered Probiotic Lactobacilli Delivery System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agentschap voor Innovatie door Wetenschap en Technologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and the efficacy of vaginally administered
      probiotic lactobacilli in combination with antibiotic therapy (metronidazole) in women with
      microbiologically defined bacterial vaginosis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proposed research project aims at the development of a vaginal probiotic delivery system to restore and to maintain the vaginal microflora</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">206</enrollment>
  <condition>Bacterial Vaginosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Probiotic lactobacilli</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Probiotic lactobacilli</intervention_name>
    <description>Probiotic lactobacilli in combination with antibiotic therapy</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo in combination with antibiotic therapy</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Untreated Bacterial Vaginosis (BV) (asymptomatic or symptomatic) as diagnosed during
             the screening visit using Amsel criteria.

          -  Otherwise healthy? pre-menopausal women between 18-50 years of age at date of
             screening.

          -  Regular menstrual cycles (21-35 days) or amenorrheic for at least 3 months due to use
             of a long acting progestin or continuous use of oral contraceptives.

          -  Subject is willing to insert vaginal applicators.

          -  Subject is willing to be asked questions about personal medical health and sexual
             history

          -  Normal Pap smear collected at the screening visit? If a subject's Visit 0 Pap smear
             result is any of the following, the person is ineligible for participation: ASC-US
             (atypical squamous cells of undetermined significance), AGC (atypical glandular
             cells), ASC-H (atypical squamous cells, cannot r/o high grade lesion), LSIL (low grade
             squamous intraepithelial lesions), HSIL (high grade squamous intraepithelial lesions),
             adenocarcinoma in situ, adenocarcinoma, squamous cell carcinoma in situ, squamous cell
             carcinoma or inadequate sample

          -  Agree to be sexually abstinent 48 hours prior to Visit 1 (enrollment) until 48 hours
             after application of the study product and a second time after visit 2.

          -  Agree to abstain from the use of any other intravaginal product (i.e., contraceptive
             creams, gels, foams, sponges, lubricants, douches, etc.) throughout the trial period.

          -  Agree to use an adequate method of birth control for the duration of the study to
             avoid pregnancy. Acceptable methods include a history of tubal ligation, male partner
             with a vasectomy, a steroidal contraceptive (oral, patch, injectable or implantable),
             IUD (Paragard or Mirena), condoms or abstinence.

          -  Subject must have access to functioning refrigerator.

        Exclusion Criteria:

          -  Urogenital infection at screening or within the 21 days prior to screening. This
             includes urinary tract infection, Trichomonas vaginalis, Neisseria gonorrhoeae,
             Chlamydia trachomatis or Treponema pallidum. Subjects may be re-screened at least 21
             days after the respective antibiotic or antifungal therapies have been completed.

          -  History of recurrent genital herpes.

          -  Diagnosis of N. gonorrhoeae, C. trachomatis, T. pallidum or T. vaginalis on two or
             more occasions during the six months prior to screening.

          -  Pregnancy or within 2 months of last pregnancy (all subjects will have a urine
             pregnancy test prior to enrollment).

          -  Lactation.

          -  Vaginal or systemic antibiotic or antifungal therapy within 21 days of the Screening
             visit or within 4 months of Enrollment visit.

          -  Investigational drug use within 4 months or 10 half-lives of the drug, whichever is
             longer, of enrollment visit. Planned investigational drug use while participating in
             this study.

          -  Menopause.

          -  IUD insertion or removal within the last 3 months.

          -  Pelvic surgery within the last 3 months.

          -  Cervical cryotherapy or cervical laser within the last 3 months.

          -  Use of a NuvaRing® within 3 days of the screening visit or during the course of the
             study.

          -  New long-acting treatments (e.g. depot formulation including medroxyprogesterone
             acetate (DMPA) form of hormonal birth control). Subjects may be enrolled if stable (&gt;
             3 months) on existing therapy as determined by the Principal Investigator.

          -  Diabetes or other significant disease or acute illness that in the Investigator's
             assessment could complicate the evaluation.

          -  Known HIV infection or positive HIV test at screening.

          -  Immunosuppressive drug within 4 months.

          -  Previous participation in a L. crispatus clinical study.

          -  Colposcopic findings at the enrollment visit involving significant deep disruption of
             the epithelium.

          -  Known allergy to any component (skim milk,…) of the drug or to latex (condoms).

          -  Unavailable for follow-up visits.

          -  History of drug or alcohol abuse.

          -  At enrollment, have any social or medical condition, or psychiatric illness that, in
             the opinion of the Investigator, would preclude provision of informed consent, make
             participation in the study unsafe, complicate interpretation of study outcome data, or
             otherwise interfere with achieving the study objectives.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marleen Temmerman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marleen Temmerman, MD, PhD</last_name>
    <email>Marleen.temmerman@ugent.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marleen Temmerman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.uzgent.be</url>
    <description>Website of the University Hospital Ghent</description>
  </link>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2008</study_first_submitted>
  <study_first_submitted_qc>September 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2008</study_first_posted>
  <last_update_submitted>June 3, 2015</last_update_submitted>
  <last_update_submitted_qc>June 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginosis, Bacterial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

